Amsterdam institute for Immunology and Infectious diseases
-
Recurrent hematological toxicity after second-line treatment in patients with glioblastoma: indication of a potential predisposition
Van Hout, L., Van den Elzen, F. E. L., De Jong, Z., Grun, N., Broen, M. P. G., Bartelink, I., Bruynzeel, A. M. E., Lagerwaard, F. J., Buter, J., Vandertop, W. P., Westerman, B. A., Lissenberg—Witte, B. I. & Kouwenhoven, M. C. M., 1 Feb 2026, In: Oncologist. 31, 2, oyaf411.Research output: Contribution to Journal › Article › Academic › peer-review
-
Model-informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records
De Carlo, A., Tosca, E. M., Crul, M., Schutte, T., van Zuijlen, L., Bahce, I., Said, M. M., Buter, J., Huls, H., Magni, P. & Bartelink, I., 2025, (Accepted/In press) In: British Journal of Clinical Pharmacology.Research output: Contribution to Journal › Article › Academic › peer-review
-
Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol
Spiekman, I. A. C., Geurts, B. S., Zeverijn, L. J., de Wit, G. F., van der Noort, V., Roepman, P., de Leng, W. W. J., Jansen, A. M. L., Kusters, B., Beerepoot, L. V., de Vos, F. Y. F. L., de Groot, D.-J. A., de Groot, J. W. B., Hoeben, A., Buter, J., Gelderblom, H. A. J., Voest, E. E. & Verheul, H. M. W., 3 May 2024, In: Oncologist. 29, 5, p. 431-440 10 p.Research output: Contribution to Journal › Article › Academic › peer-review
- All publications